ArticleGene therapy2002
hTERT promoter induces tumor-specific Bax gene expression and cell killing in syngenic mouse tumor model and prevents systemic toxicity.
Article in Gene therapy, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 92 citations in OpenAlex.
- Analysis of endogenous and exogenous tumor upregulated promoter expression in canine tumors.PloS one · 2020Article
- Review
- Functional comparison of the human epidermal growth factor receptor and telomerase reverse transcriptase promoters in canine tumor cells.The Journal of veterinary medical science · 2019Article
- Targeting strategies of adenovirus‑mediated gene therapy and virotherapy for prostate cancer (Review).Molecular medicine reports · 2017Review
- Biological ablation of sentinel lymph node metastasis in submucosally invaded early gastrointestinal cancer.Molecular therapy : the journal of the American Society of Gene Therapy · 2015Article
- Exploiting the Intron-splicing Mechanism of Insect Cells to Produce Viral Vectors Harboring Toxic Genes for Suicide Gene Therapy.Molecular therapy. Nucleic acids · 2012Article
- Gene therapy using the human telomerase catalytic subunit gene promoter enables targeting of the therapeutic effects of vesicular stomatitis virus matrix protein against human lung adenocarcinoma.Experimental and therapeutic medicine · 2012Article
- Targeting different types of human meningioma and glioma cells using a novel adenoviral vector expressing GFP-TRAIL fusion protein from hTERT promoter.Cancer cell international · 2011Article
- Deletion analysis of Ad5 E1a transcriptional control region: impact on tumor-selective expression of E1a and E1b.Cancer gene therapy · 2011Article
- Gene therapy with tumor-specific promoter mediated suicide gene plus IL-12 gene enhanced tumor inhibition and prolonged host survival in a murine model of Lewis lung carcinoma.Journal of translational medicine · 2011Article
- Targeted killing effects of double CD and TK suicide genes controlled by survivin promoter on gastric cancer cell.Molecular biology reports · 2011Article
- Targeted antitumor effect induced by hTERT promoter mediated ODC antisense adenovirus.Molecular biology reports · 2010Article
- Targeted gene therapy of nasopharyngeal cancer in vitro and in vivo by enhanced thymidine kinase expression driven by human TERT promoter and CMV enhancer.Journal of experimental & clinical cancer research : CR · 2010Article
- Improved nonviral cancer suicide gene therapy using survivin promoter-driven mutant Bax.Cancer gene therapy · 2010Article
- Potent anti-tumor effects of a dual specific oncolytic adenovirus expressing apoptin in vitro and in vivo.Molecular cancer · 2010Article
- Transgene expression of alpha tumor necrosis factor with mutations D142N and A144R under control of human telomerase reverse transcriptase promoter eradicates well-established tumors and induces long-term antitumor immunity.Cancer gene therapy · 2009Article
- Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers.Cancer science · 2008Review
- Therapeutic molecular targeting of 15-lipoxygenase-1 in colon cancer.Molecular therapy : the journal of the American Society of Gene Therapy · 2008Article
- Targeting telomerase for cancer therapeutics.British journal of cancer · 2008Review
- Carboxypeptidase-G2-based gene-directed enzyme-prodrug therapy: a new weapon in the GDEPT armoury.Nature reviews. Cancer · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
We recently showed that the human telomerase reverse transcriptase (hTERT) promoter induces tumor-specific Bax gene expression and selectively kills various human cancer cells both in vitro and in xenograft tumors. However, it remains unclear whether the hTERT promoter can be used to induce transgene expression in syngenic tumors in mice and whether Bax gene expression driven by the hTERT promoter will cause long-term, stem cell-related toxicity. To address these questions, we tested hTERT promoter-driven, adenovirus-mediated Bax transgene expression in an established syngenic mouse tumor model and its effects on tumor and normal murine tissues. The hTERT promoter was highly active in several murine tumor cell lines and a transformed cell line, but not in non-transformed and normal murine cell lines. The hTERT promoter induced tumor-specific Bax gene expression in mouse UV-2237m fibrosarcoma cells both in vitro and in vivo and suppressed syngenic tumor growth in immune-competent mice with no obvious acute or long-term toxic effects. Moreover, hTERT promoter-driven transgene expression in human CD34(+) bone marrow progenitor cells had effects similar to those observed in other normal human cells, suggesting that the hTERT promoter is much less active in CD34(+) cells than in tumor cells. Together, our data demonstrate that the hTERT promoter may allow the use of proapoptotic genes for cancer treatment without noticeable effects on progenitor cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.